2021 Annual Meeting - Integration of Surgery in the Multidisciplinary Care of Head and Neck Cancer: Focus on Oral Cavity, Larynx, and Hypopharynx Cancers
In this session, a multidisciplinary, multi-institutional group of experts will provide brief updates as to the latest techniques, approaches, outcomes, and toxicities of their modality in the treatment of patients with newly diagnosed oral cavity, larynx, and hypopharynx cancers. Our panel will include: (1) an oncologic head and neck surgeon to discuss approaches to surgical resection, neck dissection, and sentinel node biopsy; (2) a reconstructive surgeon to discuss options for functional reconstructions of head and neck resections and expected outcomes and rehabilitation; (3) a head and neck medical oncologist to discuss the role of systemic therapy (chemotherapy/immunotherapy) prior to surgery and as part of adjuvant chemoradiation; and (4) a head and neck radiation oncologist to discuss the indications for adjuvant radiation therapy, doses, targets, and techniques. After updates, there will be open discussion of a common cases, to highlight opportunities for multidisciplinary discussion and potential differences in approach. In addition, there will be discussion of clinical trials applicable to these scenarios (current, future, or waiting for results). Overall, this panel is carefully selected as a group of highly recognized, thoughtful experts with opinions on best management.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, medical oncologists, surgeons, nurses, diagnostic radiologists, pathologists and specialists.
Upon completion of this activity, participants should be able to:
- Explain the latest indications and techniques for oncologic and reconstruction surgery for head and neck cancers, focusing on cancers of the oral cavity, larynx and hypopharynx.
- Discuss the ongoing role of systemic therapy for patients treated with surgical resection for head and neck cancers, including the role of pre-operative, concurrent, and adjuvant chemotherapy, targeted therapy, and immunotherapy.
- Explain the indications for post-operative radiation for head and neck cancers treated with surgery, including dose, target, and techniques.
- Nitin Pagedar, MD, Department of Otolaryngology, University of Iowa Hospitals and Clinics has no financial relationships with a commercial interest.
- Vasu Divi, MD, Stanford University, Stanford, CA has no financial relationships with a commercial interest.
- Renata Ferrarotto, MD, Department of Thoracic Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center has investment interest from Ayala Pharmaceutical, EMD Serono, Merck, Nanobiotix, Pfizer, Regeneron-Sanofi.
- Heath D. Skinner, MD, PhD, UPMC Hillman Cancer Center has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.